.png)
TL;DRAPI, in a pharmaceutical context, stands for Active Pharmaceutical Ingredient: the substance in a medicine that actually produces the therapeutic effect. ICH Q7 defines it as any substance or mixture of substances intended to be used in the manufacture of a medicinal product that becomes an active ingredient of that product, intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to affect the structure and function of the body.
The abbreviation is worth pinning down before anything else, because outside pharmaceutical manufacturing it almost always means something else. In software, API means Application Programming Interface. In energy, it means the American Petroleum Institute. In a general web search the pharmaceutical meaning barely appears. Everything below concerns the pharmaceutical meaning only. If you arrived here looking for the software sense of the word, this is not the page you want.
The ambiguity is not merely an annoyance for search engines. It causes real errors in procurement and in integration projects, where a request for "API access" and a request for "API sourcing" belong to different departments entirely, and where a supplier questionnaire that asks for "the API" will get a URL from one team and a CAS number from another. In pharmaceutical documents, assume Active Pharmaceutical Ingredient unless the context is explicitly about software.
Several synonyms appear constantly and mean the same thing. ICH Q7 itself uses drug substance as an equivalent term, and its glossary heading reads "Active Pharmaceutical Ingredient (API) (or Drug Substance)". In EU law the term is active substance. In German law it is Wirkstoff. In US regulations it is active ingredient. The concept is stable across all four; only the label moves. This matters when reading a dossier that was assembled across jurisdictions, because a single product file can use three of these words for one substance without any of them being wrong.
An API does the pharmacological work. An excipient is defined by exclusion: it is everything else in the medicine. This sounds like a technicality, and it is exactly the opposite, because the regulatory burden attached to a substance follows from which side of this line it falls on.
| Active pharmaceutical ingredient | Excipient | |
|---|---|---|
| Function | Furnishes pharmacological activity or other direct effect in diagnosis, cure, mitigation, treatment or prevention of disease, or affects the structure and function of the body | Everything else: carrier, filler, binder, preservative, colourant, solvent |
| EU definition | Active substance, Directive 2001/83/EC Art. 1(3a) | Any constituent of a medicinal product other than the active substance and the packaging material, Art. 1(3b) |
| German definition | Wirkstoff, section 4 para. 19 AMG | Hilfsstoff: any constituent of a medicinal product except the active substance and the packaging material, section 4 para. 20 AMG |
| US definition | Active ingredient, 21 CFR 210.3(b)(7) | Inactive ingredient: any component other than an active ingredient, 21 CFR 210.3(b)(8) |
| GMP standard | ICH Q7 applies in full | Not covered by ICH Q7 |
Note how consistent the drafting is. Three of the four jurisdictions define the excipient purely negatively, as whatever is not the active substance. The API is the anchor definition, and the excipient is the remainder. Note also the German and EU wording explicitly excludes the packaging material from the excipient category, which the US wording does not.
Most published material on APIs stays inside one jurisdiction, which is unhelpful, because an API is almost never made, released and consumed inside one. The table below is the cross-jurisdiction view.
| ICH | EU | Germany | US | |
|---|---|---|---|---|
| Term used | Active Pharmaceutical Ingredient (API), or drug substance | Active substance | Wirkstoff | Active ingredient |
| Definition anchor | ICH Q7, glossary | Directive 2001/83/EC, Art. 1(3a) | AMG, section 4 para. 19 | 21 CFR 210.3(b)(7) |
| GMP standard | ICH Q7, Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, reached Step 4 on 10 November 2000 | ICH Q7 as an EMA scientific guideline, ref. CPMP/ICH/4106/00, effective 1 November 2000 | AMWHV, the ordinance on GMP for the manufacture of medicinal products and active substances | ICH Q7 as adopted by the ICH regulatory parties |
| Duty to notify or register | Not applicable, ICH issues guidance not law | Importers, manufacturers and distributors of active substances established in the Union must register with the competent authority at least 60 days before starting the activity, Art. 52a | Notification duty under AMG section 67 para. 1; a manufacturing authorisation under AMG section 13 para. 1 no. 3 is required for active substances of human, animal or microbial origin, or produced by genetic engineering | Not covered here |
| Import rule | Not applicable | Active substances may only be imported if made to GMP at least equivalent to EU standards and accompanied by a written confirmation from the competent authority of the exporting third country, Art. 46b(2) | Follows the EU rule via the AMG | Not covered here |
The import rule in Art. 46b(2) deserves a second look, because it is the clause that reaches outside the Union and shapes global API sourcing. An active substance may only be imported into the EU if it was manufactured to GMP standards at least equivalent to those the Union lays down, and if it arrives accompanied by a written confirmation from the competent authority of the exporting third country attesting to that. The obligation in Art. 46b(1) is broader still: member states must ensure that the manufacture, import and distribution of active substances on their territory complies with good manufacturing practice and good distribution practice, including active substances that are intended for export.
The German split is the detail that surprises people most often. A chemically synthesised API does not require a manufacturing authorisation under section 13 AMG. The authorisation requirement in section 13 para. 1 no. 3 covers active substances of human, animal or microbial origin, or those made by genetic engineering. For the rest, the notification duty under section 67 AMG applies instead. So "does this API plant need a Herstellungserlaubnis" has no general answer; it depends on the origin of the substance.
Vendor material tends to slice API types by marketing category: small molecule, biologic, high potency. ICH Q7 slices them by manufacturing route, which is more useful, because the route is what decides how the guide applies.
| Manufacturing route | Covered by ICH Q7 | Qualification |
|---|---|---|
| Chemical synthesis | Yes | GMP applies from the point at which the API starting material enters the process |
| Extraction | Yes | Rationale for the GMP starting point set case by case |
| Cell culture and fermentation | Yes | Cell substrates and early process steps may be subject to GMP but are not covered by the guide |
| Recovery from natural sources | Yes | Rationale for the GMP starting point set case by case |
| Sterile APIs | Partly | Only up to the point immediately prior to the API being rendered sterile; sterilisation and aseptic processing are not covered |
| Medical gases, bulk-packaged medicinal products, radiopharmaceutical-specific aspects | No | Excluded from the scope of the guide |
The single most consequential sentence in ICH Q7 is about where GMP begins, because it decides how far up a supply chain the audit obligation reaches:
Read together, those five points mean the GMP boundary is not fixed by the regulator. It is proposed by the company and has to be justified. That is why the choice of starting material is a recurring inspection topic rather than a paperwork exercise.
Active substances are not a single field on pharmazie.com. They are a layer, reached from either direction: from a substance down to every product that contains it, or from a PZN up to the substance and its salt forms.
One honest limitation: this is substance data as it appears in authorised finished medicinal products, not manufacturing data. For the GMP status of an API manufacturing site, its inspection history, or a Certificate of Suitability or Active Substance Master File, the authoritative sources are the EudraGMDP database and the EDQM, and no article database substitutes for either.
